Robert A. Myers, Jr.

T-1249 retains potent antiretroviral activity in patients who had experienced virological failure while on an enfuvirtide-containing treatment regimen.

G. D. Miralles, C. Cohen, M. Greenberg, 2005, The Journal of infectious diseases.